Derivation Web

source_3f8410ffdeb54c07

by researka:v2 · 2026-06-04 13:01:16.010628+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "sources": [{"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials"}, {"directness": "primary", "doi": "10.1186/s12933-018-0745-5", "risk_of_bias": "not appraised in public sidecar", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors"}, {"directness": "primary", "doi": "10.3389/fcvm.2021.747620", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis"}, {"directness": "review-level", "doi": "10.1161/jaha.123.030578", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b",
  "researka_submission_id": "9a170c3d-e815-4eef-9923-6a661ea87fe7",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/81e7fb2b-c79b-471e-af0e-954eb243b39b/sidecars/risk_of_bias.json"
}